Literature DB >> 20175274

Toxic vitreitis outbreak after intravitreal injection.

Thomas Ness1, Niklas Feltgen, Hansjuergen Agostini, Daniel Böhringer, Beate Lubrich.   

Abstract

PURPOSE: To report clinical and epidemiologic findings of 11 patients with severe intraocular inflammation after intravitreal injection.
METHODS: This is a single-center, retrospective, interventional case series of 11 patients with severe intraocular inflammation after intravitreal injection at 1 referral center. The clinical data of all patients (3,357) who underwent intravitreal injection between February 2007 and February 2008 were analyzed. All incidents of postoperative intraocular inflammatory reaction were documented.
RESULTS: During the examination period, we identified 11 cases of intraocular inflammation after intravitreal injection. Only one thereof was infectious endophthalmitis with retinal abscess. All others were toxic vitreitis. Seven eyes exhibited hypopyon and five disseminated retinal hemorrhages. The toxic reaction occurred within 48 hours after injection, whereas in the endophthalmitis case, it occurred after 72 hours. We believe that the cause of this reaction was the particular syringe brand used. After changing to another syringe brand, no further cases of toxic vitreitis occurred during the next 6 months.
CONCLUSION: Toxic inflammatory reaction is not only a complication of cataract surgery, but may also occur after intravitreal injection. A critical review of all processes involved and materials used would help to prevent further cases of toxic vitreitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20175274     DOI: 10.1097/iae.0b013e3181baf691

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  15 in total

1.  Quality of bevacizumab compounded for intravitreal administration.

Authors:  J M Palmer; W M Amoaku; F Kamali
Journal:  Eye (Lond)       Date:  2013-06-21       Impact factor: 3.775

2.  Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling.

Authors:  Lu Liu; David A Ammar; Lindsey A Ross; Naresh Mandava; Malik Y Kahook; John F Carpenter
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-22       Impact factor: 4.799

3.  Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model.

Authors:  Wenbo Zhang; Harumasa Yokota; Zhimin Xu; Subhadra P Narayanan; Lauren Yancey; Akitoshi Yoshida; Dennis M Marcus; Robert W Caldwell; Ruth B Caldwell; Steven E Brooks
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-11       Impact factor: 4.799

4.  [Endophthalmitis].

Authors:  Thomas Neß
Journal:  Ophthalmologe       Date:  2018-08       Impact factor: 1.059

5.  Endophthalmitis following intravitreal injections.

Authors:  Cristina Irigoyen; Kimia Ziahosseini; George Morphis; Theodor Stappler; Heinrich Heimann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-03       Impact factor: 3.117

6.  Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab.

Authors:  Andre J Witkin; Paul Hahn; Timothy G Murray; J Fernando Arevalo; Kevin J Blinder; Netan Choudhry; Geoff G Emerson; Roger A Goldberg; Stephen J Kim; Joel Pearlman; Eric W Schneider; Homayoun Tabandeh; Robert W Wong
Journal:  J Vitreoretin Dis       Date:  2020-07-01

7.  Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis.

Authors:  Andre J Witkin; Paul Hahn; Timothy G Murray; J Fernando Arevalo; Kevin J Blinder; Netan Choudhry; Geoff G Emerson; Roger A Goldberg; Stephen J Kim; Joel Pearlman; Eric W Schneider; Homayoun Tabandeh; Robert W Wong
Journal:  J Vitreoretin Dis       Date:  2020-12-15

8.  [Reliability and safety of intravitreal Ozurdex injections. The ZERO study].

Authors:  K Schmitz; M Maier; C R Clemens; F Höhn; J Wachtlin; F Lehmann; T Bertelmann; K Rüdiger; M Horn; A Bezatis; G Spital; C H Meyer
Journal:  Ophthalmologe       Date:  2014-01       Impact factor: 1.059

9.  Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway.

Authors:  Hua Liu; Wenbo Zhang; Zhimin Xu; Robert W Caldwell; Ruth B Caldwell; Steven E Brooks
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

10.  Assessment of bevacizumab quality and stability in repackaged syringes for clinical use.

Authors:  A Santoveña; E Sánchez-Negrín; F Gutiérrez; J Nazco; J B Fariña
Journal:  Eur J Hosp Pharm       Date:  2016-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.